Associations between these somatic mutations and disease phenotype or prognosis have been suggested, e.g., co-occurrence of TET2 and SRSF2 mutations is common in CMML and specific for myeloid neoplasms with monocytosis [1]; the mutations in ASXL1, NRAS, RUNX1, or SETBP1 are associated with an unfavorable prognosis [8], whereas mutated TET2 with wild type ASXL1 (muTET2/wtASXL1) is associated with a favorable CMML prognosis [9]. This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.